Its valuation is considered fairly valued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at max_target_price.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Nautilus Biotechnology Inc's Score
Industry at a Glance
Industry Ranking
210 / 501
Overall Ranking
370 / 4682
Industry
Biotechnology & Medical Research
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Strong Buy
Current Rating
2.500
Target Price
+23.15%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Nautilus Biotechnology Inc Highlights
StrengthsRisks
Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -2.59, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 57.12M shares, decreasing 6.05% quarter-over-quarter.
Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
Ticker SymbolNAUT
CompanyNautilus Biotechnology Inc
CEOPatel (Sujal)
Websitehttps://www.nautilus.bio/
FAQs
What is the current price of Nautilus Biotechnology Inc (NAUT)?
The current price of Nautilus Biotechnology Inc (NAUT) is 1.980.
What is the symbol of Nautilus Biotechnology Inc?
The ticker symbol of Nautilus Biotechnology Inc is NAUT.
What is the 52-week high of Nautilus Biotechnology Inc?
The 52-week high of Nautilus Biotechnology Inc is 2.540.
What is the 52-week low of Nautilus Biotechnology Inc?
The 52-week low of Nautilus Biotechnology Inc is 0.620.
What is the market capitalization of Nautilus Biotechnology Inc?
The market capitalization of Nautilus Biotechnology Inc is 250.08M.
What is the net income of Nautilus Biotechnology Inc?
The net income of Nautilus Biotechnology Inc is -70.78M.
Is Nautilus Biotechnology Inc (NAUT) currently rated as Buy, Hold, or Sell?
According to analysts, Nautilus Biotechnology Inc (NAUT) has an overall rating of --, with a price target of 2.500.
What is the Earnings Per Share (EPS TTM) of Nautilus Biotechnology Inc (NAUT)?
The Earnings Per Share (EPS TTM) of Nautilus Biotechnology Inc (NAUT) is -0.498.